WVE-007
Low EvidenceWVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing.
What It Is
WVE-007 is a long-acting, GalNAc-conjugated small interfering RNA (siRNA) designed to knock down INHBE, the liver gene that encodes the hepatokine Activin E. Activin E signals through the receptor ALK7 (encoded by ACVR1C) on fat cells, where it suppresses lipolysis and promotes fat storage. Human genetics is the foundation of the program: people who carry rare loss-of-function variants in INHBE have a lower waist-to-hip ratio and a favorable cardiometabolic profile - less abdominal fat, lower triglycerides, higher HDL and reduced risk of type 2 diabetes - without adverse consequences, and ALK7 (ACVR1C) loss-of-function variants produce a similar phenotype. WVE-007 is engineered to pharmacologically mimic that protective genetics by silencing INHBE in the liver, lowering circulating Activin E, releasing the brake on adipose lipolysis and shifting the body toward fat loss while sparing muscle. This mechanism is fundamentally different from GLP-1 and amylin drugs, which work through appetite suppression; WVE-007 instead reprograms how fat tissue stores and mobilizes energy, and it is being positioned both as a potential standalone therapy and as a combination partner that could improve the 'quality' of weight loss achieved with incretins. Wave Life Sciences is testing WVE-007 in the Phase 1 INLIGHT trial. In interim data reported in December 2025, a single 240 mg subcutaneous dose improved body composition at three months versus baseline - a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (about 3.5 lb; p=0.07) and a 3.2% increase in lean mass (about 4.0 lb; p=0.01) - fat loss described as similar to GLP-1 therapy at three months but without the muscle loss that often accompanies incretin-driven weight loss. Six-month interim data reported in March 2026 showed continued, placebo-adjusted reductions in visceral fat (about -14%; p<0.05), total fat (about -5%), waist circumference (about -3%) and body weight (about -1%), with lean mass stabilized (about +2%). Serum Activin E reductions were durable, supporting the potential for infrequent - once- or twice-yearly - dosing, and the drug was generally safe and well tolerated with only mild treatment-related adverse events and no clinically meaningful changes in lipids or liver function tests. Wave initiated the Phase 2a portion of INLIGHT in people with higher BMI (35-50 kg/m2) and comorbidities in the second quarter of 2026, with data intended to inform development across obesity, MASH, type 2 diabetes and cardiovascular disease. WVE-007 reflects a broader 2026 shift toward genetically validated, adipose-directed mechanisms - including the Activin E/ALK7 pathway also pursued by Arrowhead's ARO-INHBE and ARO-ALK7 - that seek to preserve lean mass as a defining advantage over incretin monotherapy.
Regulatory Status
In Phase 1/2 clinical development (INLIGHT trial); Phase 2a portion initiated Q2 2026. Interim Phase 1 data only; no regulatory filing and not approved in any jurisdiction as of mid-2026.
Effective: 2026
View FDA SourceWhy Researchers Study It
WVE-007 tests whether an old genetic clue can be turned into a drug: humans born with INHBE loss-of-function are naturally leaner in the abdomen and metabolically healthier, so silencing INHBE pharmacologically could reproduce that protection. Its appeal is a mechanism that drives fat loss while preserving - or even increasing - lean mass, which addresses one of the main criticisms of GLP-1-based weight loss, plus the possibility of once- or twice-yearly dosing thanks to durable target knockdown.
Proposed Mechanisms
- Silences INHBE messenger RNA in hepatocytes via a GalNAc-conjugated siRNA, reducing production of the hepatokine Activin E
- Lowers circulating Activin E, decreasing signaling through the ALK7 (ACVR1C) receptor on adipocytes
- Relieves Activin E-mediated suppression of adipose lipolysis, shifting fat tissue toward energy mobilization and fat loss
- Preserves or increases lean mass by acting on fat storage rather than suppressing appetite, unlike GLP-1 and amylin agonists
- Produces durable target knockdown enabling potential once- or twice-yearly subcutaneous dosing
- Pharmacologically mimics the protective phenotype of human INHBE and ALK7 loss-of-function variants
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 1 (interim, 3-month) | INLIGHT trial - single 240 mg subcutaneous dose in adults with overweight/obesity | At 3 months vs baseline: visceral fat -9.4% (p=0.02), total body fat -4.5% (~3.5 lb; p=0.07), lean mass +3.2% (~4.0 lb; p=0.01); fat loss similar to GLP-1 at 3 months without muscle loss; well tolerated | Source |
| Phase 1 (interim, 6-month) | INLIGHT trial - single subcutaneous dose, placebo-adjusted follow-up | At 6 months (placebo-adjusted): visceral fat ~-14% (p<0.05), total fat ~-5%, waist circumference ~-3%, body weight ~-1%, lean mass stabilized (~+2%); durable serum Activin E reductions supporting once- or twice-yearly dosing; favorable safety with mild TRAEs and no meaningful lipid/LFT changes | Source |
| Human genetics rationale | UK Biobank / exome analyses of INHBE and ACVR1C (ALK7) variants | Rare loss-of-function variants in INHBE associate with lower waist-to-hip ratio and a favorable metabolic profile (lower triglycerides, higher HDL, reduced type 2 diabetes risk); ALK7 (ACVR1C) variants show a similar protective phenotype | Source |
Commonly Discussed Benefits
Researching WVE-007? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Early clinical stage - only interim Phase 1 data from a single trial; efficacy and safety are not established
- Weight loss to date is modest (~1% at 6 months); the value proposition rests on body composition (fat loss with lean-mass preservation), which must be confirmed in larger, longer trials
- Long-term safety of durable INHBE/Activin E silencing in humans is unknown
- As an investigational RNAi therapeutic it is delivered only within clinical trials; not FDA-approved and not a compounding-eligible peptide
- Any 'WVE-007' or 'INHBE siRNA' offered by a vendor is unverified - it is a proprietary investigational candidate
- Not a dietary supplement or research chemical; it is a prescription-track biologic in development
Comparisons
See how WVE-007 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Wave Life Sciences - Positive Interim Phase 1 INLIGHT Data at Six Months for WVE-007 (Mar 26, 2026) PubMed
- [2] Wave Life Sciences - Positive Interim Phase 1 INLIGHT Data at Three Months for WVE-007 (Dec 8, 2025) PubMed
- [3] Wave Life Sciences - Initiation of Phase 2a Portion of INLIGHT for WVE-007 (INHBE GalNAc-siRNA) PubMed
- [4] Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity (Nature Communications, 2022) PubMed
Keep researching in the app
- Log WVE-007 to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Retatrutide
High EvidenceAn investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.
MariTide
High EvidenceA bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes.
Bimagrumab
Medium EvidenceAn anti-activin type II receptor antibody that promotes fat loss while preserving lean muscle mass, studied in combination with GLP-1 agonists for obesity.
Taldefgrobep Alfa
Low EvidenceA novel myostatin-activin pathway inhibitor targeting fat reduction and lean mass gain, with Phase 2 results in obesity expected H2 2026.
Trevogrumab
Medium EvidenceTrevogrumab (REGN1033) is an investigational fully human anti-myostatin (anti-GDF8) monoclonal antibody from Regeneron being tested as a lean-mass-sparing add-on to semaglutide in the Phase 2 COURAGE obesity trial; adding it to semaglutide prevented roughly half of the ~33% of GLP-1-induced weight loss that normally comes from muscle, and the semaglutide + trevogrumab + garetosmab triplet reached 13.4% weight loss at 26 weeks with only ~7.4% of that loss from lean mass.
Pelacarsen
Medium EvidenceA first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026.
Olpasiran
Medium EvidenceAn investigational, once-every-12-weeks injectable small interfering RNA (siRNA) from Amgen that lowers lipoprotein(a) [Lp(a)] by up to ~97% by silencing the LPA gene in the liver. Its Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial (~7,000 patients) is one of the pivotal readouts — due December 2026 — that will help decide whether lowering Lp(a) prevents heart attacks and strokes.
Lepodisiran
Medium EvidenceAn investigational, long-duration injectable small interfering RNA (siRNA) from Eli Lilly that lowers lipoprotein(a) [Lp(a)] by nearly 94% by silencing the LPA gene in the liver. A single dose keeps Lp(a) suppressed for a year or more, and its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes trial to include people who have not yet had a cardiovascular event.
Zerlasiran
Medium EvidenceAn investigational, long-acting injectable small interfering RNA (siRNA) from Silence Therapeutics that lowers lipoprotein(a) [Lp(a)] by more than 80% by silencing the LPA gene in the liver. Dosed only every 16–24 weeks, it produced durable ~90% reductions in its Phase 2 ALPACAR-360 trial (published in JAMA, 2024); as of 2026 the company is seeking a partner before starting its Phase 3 cardiovascular outcomes study.